Klaria Pharma Q2: Focus on sealing the deal - Redeye

Redeye comments on Klaria Pharma’s Q2 2023 report. Despite the recent rights issue at the end of 2022, which generated SEK59.2m in gross proceeds, we note that the company needs to strengthen its cash position before the year-end. While we anticipate a rights issue around year-end, we highlight the possibility of capital injections via its partnerships and/or a licensing agreement with its sumatriptan alginate film, which could fully or partially offset the need for a dilutive equity raise.

Länk till analysen i sin helhet: https://www.redeye.se/research/939893/klaria-pharma-q2-focus-on-sealing-the-deal?utm_source=finwire&utm_medium=RSS